122PostersPosterNON-ONCOLOGICAL HEMATOLOGYPO-098DUAL EFFECT OF ARSENIC TRIOXIDE ON HEMOPOIESIS:INHIBITION OF ERYTHROPOIESIS AND STIMULATION OFMEGAKARYOCYTOPOIESISSaulle E, Riccioni R, Pelosi E, Rossini A, Petrucci E,Pasquini L, De Tuglie G, Calabrò L, Stafsnes M,Peschle C, Testa UDipartimento di Ematologia, Oncologia e Medicinamolecolare, Istituto Superiore di Sanità, Rome, ItalyArsenic compounds, including arsenic trioxide(As2O3) and arsenic disulfide, utilized in some traditionalChinese remedies, have been demostrated to beeffective for the treatment of Acute PromyelocyticLeukemia (APL), when used at low doses. However,As2O3 is also a potent inducer of apoptosis in a numberof other cancer cells such as AML, gastric cancer,neuroblastoma. The exact mechanism of As203induced apoptosis in the cells is <strong>no</strong>t yet clear. In thepresent study we investigated the effect of As2O3 onerythropoiesis and megakaryocytopoiesis. DuringAs203 treatment of the human erythroleukemic cellline HEL several changes were observed: stimulatio<strong>no</strong>f megakaryocytic differentiation, inhibition of severalerythroid markers and induction of apoptosis atthe same time. Particularly,the expression of erythroid-specificreceptors such as c-Kit, Epo-R, GlycA,were downmodulated after As2O3 exposure. Similarobservations have been made in K562 cells. The samephe<strong>no</strong>me<strong>no</strong>n was observed during unilineage erythroidand megakaryocytic cultures from <strong>no</strong>rmalhemopoietic progenitor cells : blockade of erythropoiesisand stimulation of megakaryocytopoiesis, asshown by cell cycle, morphologic and immu<strong>no</strong>phe<strong>no</strong>typicanalyses. To determine whether the engagmentof caspases is involved in these phe<strong>no</strong>mena weanalyzed the expression of GATA-1 and Tal-1 transcriptionfactors, two targets of caspases, whoseintegrity and activity is essential for the developmentand survival of the erythroid lineage. After exposureof HEL and K562 cells to As203 for 48h we observeda decrease of GATA-1 and Tal-1 expression; moreover,treatment with pan-caspase inhibitor z-VAD incombination with As203, protects GATA-1 fromcleavage. In unilineage cultures of <strong>no</strong>rmal erythroidprogenitors the addition of As203 resulted in a blockadeof erythroid maturation at the proerythroblasticstage, associated with a cleavage of both GATA-1and Tal-1 transcription factors. Both the As203-induced inhibition of erythroid cell differentiationand cleavage of transcription factors was blocked byzVAD. In contrast, the addition of As203 to unilineagecultures of <strong>no</strong>rmal megakaryocytic precursors did <strong>no</strong>tinduce any cleavage of GATA-1 and Tal-1 transcriptionfactors and induced a stimulation of megakaryocyticmaturation (i. e. , increase in the formation ofthe large polyploid megakaryocytes). The stimulatoryeffect of As203 on megakaryocytic maturationseems to require caspase activation. Experiments arein progress to determine the caspase required for theinhibitory and stimulatory effect of As203 on erythropoiesisand megakaryocytopoiesis, respectively.Our results clearly indicate that the effects of As203on hematopoiesis are lineage specific and the markedinhibitory effect of this compound on erythropoiesiscould explain the development of anemia ofte<strong>no</strong>bserved during therapy based on As2O3 administration.PO-099USE OF THE BLOB ANALYSIS IN THE DEVELOPMENT OF A NEWPROCEDURE FOR THE AUTOMATIC COUNT OF GRANULOCYTESMIGRATING THROUGH MICROPORE FILTERS IN CHEMOTACTICBOYDEN CHAMBERAzzarà A, Chimenti M,* Carulli G, Galimberti S,Fazzi R, Andreazzoli F, Petrini MDivisione di Ematologia, Dipartimento di Oncologia,dei Trapianti e delle Nuove tec<strong>no</strong>logie in Medicina,Università di Pisa, Italy; Divisione di Ematologia,Dipartimento di Oncologia, dei Trapianti e delleNuove tec<strong>no</strong>logie in Medicina, Università di Pisa,Italy; * Istituto Di Scienza e Tec<strong>no</strong>logie dell'Informazione“A. Faedo”. Consiglio Nazionale delle Ricerche,Pisa, ItalyIn this paper we describe a completely new imageprocessing procedure for an automatic assessmentof granulocyte motility in micropore filters. Granulocytemotility was evaluated in perspex chemotacticchambers according to the Boyden method, usingmixed-ester filters between the two compartments.After treatment, the filters were fixed, dehydrated,stained, diaphanized and placed on the electromechanicaltable of a Leitz Hortolux microscope.According to our procedure, the objective is focusedon the upper plane of the filter and a sequence of digitalimages is then acquired at predetermined depthsby means of a video camera. The video signal is sentto a video board which can store digital imagesdefined by 768×576 pixels with 300 µm spatial resolution.The frame grabber works on a personal computerunder the control of the Matrox Inspector(R)software, which uses several options, such as Seg-haematologica vol. <strong>89</strong>[suppl. n. 6]:september <strong>2004</strong>
VIII Congress of the Italian Society of Experimental Hematology, Pavia, September 14-16, <strong>2004</strong>123mentation, Setting and Features. Initially, a decisionthreshold is properly selected, according to agreyscale segmentation threshold. Then, regions oftouching pixels are automatically identified by thesoftware as a blob, each blob corresponding to a cellin the processed image. Setting allows the definitio<strong>no</strong>f the Foreground and the option Remove Blobsregards the situation of Touching Blobs, or the definitio<strong>no</strong>f Minimum Area or Maximum Area (expressedin pixel2). Each image is processed in order to revealthe blobs, produced by the granulocytes, and toextract the plane coordinates (x,y) of the centroid ofeach blob. The results obtained by processing the firstimage of the sequence are compared with the resultsobtained by processing the second one, in order todetect couples of blobs having the same plane coordinatesand to delete one of them. This comparisonis performed considering the results obtained fromsecond and third images, and so on. The completeprocedure is performed in few seconds. The automaticanalysis was compared blind with a traditionalanalysis performed by an optical detection of thecells in each plane: <strong>no</strong> statistical differences werefound between the two sequences, except for theplane corresponding to 20 µm, wich resulted criticalin the visual way, showing a bias due to the focusingof a large amount of cells under examination, whichleads to count twice the same cells. On the contrarythe software was able to eliminate this artifactualeffect, by recognizing each cell and assigning it to theplane in which it really is. So the procedures performsa reliable and reproducible count of the of the granulocytesin the micropore filters ( without underestimatio<strong>no</strong>r overestimation) and determines <strong>no</strong>t onlythe depth reached by the cells, but also their truepropagation curve.PO-100IMMUNOREGULATORY EFFECT OF PR-39, AN ANTIMICROBIALPEPTIDEMalinverni R, Gritti D, Malinver<strong>no</strong> A, Culacciati D,Gasparetto C, Ross C, § Ricevuti GDipartimento di Medicina Interna e Terapia Medica,Università degli Studi di Pavia, Clinica Medica III,IRCCS Policlinico S. Matteo, Pavia; § Department ofAnatomy and Physiology, Kansas State University,USAIntroduction. Neutrophil antimicrobial peptides arecontained in azurophilic grains of the neutrophil andhave microbicidal properties. They are also secretedby many epithelial cells, and many antimicrobial peptideshave additional effects on innate immunity. PR-39 is a proline-arginine rich antimicrobic peptide,belonging to the sub-family of the cathelicidins. PR-39 was cloned in 1993 from the pig neutrophil. PR-39 blunts neutrophil activation by binding to intracellularSH3 domains during NAD(P)H oxidase assembly.The evidence for the existence of a neutrophiltypeNAD(P)H oxidase in platelets, has been confirmedby the identification of the subunit p67phox,p47phox and a gp91phox. Platelets (PLTs) producereactive oxygen subspecies (ROS) that stimulatedplatelet aggregation and the interaction with neutrophils.PLTs activation is thought to be a key inacute vascular thrombosis. Therefore, prevention ofenhanced platelet activation is a major target of therapeuticstrategies fighting cardiovascular and cerebrovasculardiseases. Since the platelet NAD(P)H oxidasepresents a potential target for PR-39, the aim ofour study was to verify if the PR-39 interferes withactivation, aggregation, production of platelet ROSand platelets-neutrophil interaction. Methods. Westudied the effect of 2 concentrations of PR-39 (5µM,1µM) on platelet function. Platelet Rich Plasma (PRP)or whole blood, incubated with or without PR-39,was tested for aggregation, ROS production and PLT-PMN interaction with and without stimulus. Dihydrorhodamine-123(DHR-123) was used to examinein vitro platelets ROS production with a flow cytometricmethod. 12-phobol-13-myristate acetate(PMA), and f-met-leu-phe (fMLP) were used as agonists.Data are expressed as fluorescence mean intensity(FMI). PLT-PMN complexes were measured usingflow cytometry. Data are expressed as percent of neutrophilswhich co-localized with PLT markers underbasal condition and after blood stimulation with ADP,fMLP or PMA. Platelet aggregation was studied usedPRP stimulated with ADP or thrombin in a CHRONO-LOG aggregometer. Results. PR-39 had <strong>no</strong> affect onplatelet aggregation. PR-39 at 1 µM had <strong>no</strong> affect onplatelet ROS production while PR-39 5 µM inhibitedfMLP- (5.307 FMI±0.729 vs 3.5<strong>89</strong> FMI±0.885,p
- Page 1 and 2:
haematologicahJournal of Hematology
- Page 3:
haematologicaeditorial boardeditor-
- Page 6:
supplement 6, September 2004Table o
- Page 9 and 10:
VIII Congress of the Italian Societ
- Page 11 and 12:
VIII Congress of the Italian Societ
- Page 13 and 14:
VIII Congress of the Italian Societ
- Page 15 and 16:
VIII Congress of the Italian Societ
- Page 18 and 19:
12Main ProgramAcknowledgments: this
- Page 20 and 21:
14Main Programhaematologica vol. 89
- Page 22 and 23:
16Oral Communicationsexpression. TR
- Page 24 and 25:
18Oral CommunicationsBEST-06NK CELL
- Page 26 and 27:
20Oral Communications: Molecular He
- Page 28 and 29:
22Oral Communications: Molecular He
- Page 30 and 31:
24Oral Communications: Hematopoieti
- Page 32 and 33:
26Oral Communications: Hematopoieti
- Page 34 and 35:
28Oral Communications: Hematopoieti
- Page 36 and 37:
30Oral Communications: Non-malignan
- Page 38 and 39:
32Oral Communicationsmodulation of
- Page 40 and 41:
34Oral Communicationsfollow-up samp
- Page 42 and 43:
36Oral Communicationsinary results
- Page 44 and 45:
38Oral Communicationslow-grade NHL)
- Page 46 and 47:
40Oral CommunicationsOral Communica
- Page 48 and 49:
42Oral Communicationsboth increased
- Page 50 and 51:
44Oral CommunicationsCO-40POTENTIAL
- Page 52 and 53:
46Oral Communicationsshowed an exte
- Page 54 and 55:
48Oral CommunicationsThe molecular
- Page 56 and 57:
50Oral Communicationsthe transcript
- Page 58 and 59:
52Oral Communicationsing to apoptot
- Page 60 and 61:
54Oral CommunicationsCO-54NEOPLASTI
- Page 62 and 63:
56Oral CommunicationsOral Communica
- Page 64 and 65:
58Oral Communicationssystem-Promega
- Page 66 and 67:
60Oral Communicationsthe relationsh
- Page 68 and 69:
62PostersPosterACUTE MYELOID LEUKEM
- Page 70 and 71:
64Postersone course of CI-FLA. Ther
- Page 72 and 73:
66Postersed to GST deletions and CY
- Page 74 and 75:
68Posterstion until optimal VPA pla
- Page 76 and 77:
70Posterseffective biotechnological
- Page 78 and 79: 72Postersdirectly to maintenance th
- Page 80 and 81: 74PostersPosterACUTE LYMPHOID LEUKE
- Page 82 and 83: 76Postersformed in half the patient
- Page 84 and 85: 78Posterspatients correlating data
- Page 86 and 87: 80Postersleukemia-related and thus
- Page 88 and 89: 82PostersCD33/CD16, CD13/CD16, CD45
- Page 90 and 91: 84PostersIn myelodysplastic syndrom
- Page 92 and 93: 86Postersin our series of 376 conse
- Page 94 and 95: 88PostersPO-041FUNCTIONAL ANALYSIS
- Page 96 and 97: 90PostersPO-044FISHING NUP98 INVOLV
- Page 98 and 99: 92Postersof AML blasts to RA. In su
- Page 100 and 101: 94Postersafter 72-96 h treatment wi
- Page 102 and 103: 96PostersPosterMOLECULAR HEMATOLOGY
- Page 104 and 105: 98Postersanalyse the transcribed HU
- Page 106 and 107: 100Postersed with the gain of the i
- Page 108 and 109: 102Postershowever, been reported in
- Page 110 and 111: 104Postersand the intrinsic apoptot
- Page 112 and 113: 106Postersferentation by BM stromal
- Page 114 and 115: 108PostersPO-075NONMYELOABLATIVE AL
- Page 116 and 117: 110Posters9-12, 17-20/28 d on odd c
- Page 118 and 119: 112PostersPosterMULTIPLE MYELOMA II
- Page 120 and 121: 114Posterssion, the immunomodulator
- Page 122 and 123: 116Posters(p-ERK1/2) levels in myel
- Page 124 and 125: 118PostersPO-092ROLE OF THE MEVALON
- Page 126 and 127: 120Postershis study evaluates the p
- Page 130 and 131: 124PostersPO-101A WHOLE BLOOD FLOW
- Page 132 and 133: 126Postersthat ITP DCs, after pulsi
- Page 134 and 135: 128PostersTherefore in the proposit
- Page 136 and 137: 130Postersods and early effective a
- Page 138 and 139: 132PostersPO-116FIP1L1-PDGFRA FUSIO
- Page 140 and 141: 134Postersand of course, as reducti
- Page 142 and 143: 136Posterscurrently under study bec
- Page 144 and 145: 138Postersmg/day (Haematologica 200
- Page 146 and 147: 140Postersno severe reaction were o
- Page 148 and 149: 142PostersCML for clinical and haem
- Page 150 and 151: 144PostersPO-135THE ATG-SAPORIN-S6
- Page 152 and 153: 146Postersthrough a flow cytometry-
- Page 154 and 155: 148Posterspredominant TCR peak prec
- Page 156 and 157: 150Postersrejection or cytopenia, w
- Page 158 and 159: 152Postersphocytes. Anti-leptin blo
- Page 160 and 161: 154Postersmy), which the patient re
- Page 162 and 163: 156Postersgr/m 2 +GCSF) followed by
- Page 164 and 165: 158Postersremission of 100% of MCL
- Page 166 and 167: 160Posterswould require an early an
- Page 168 and 169: 162PostersPO-165SPONTANEOUS MOBILIZ
- Page 170 and 171: 164PostersPO-168TLR7 AND TLR9 LIGAN
- Page 172 and 173: 166PostersFR and/or CDR clustering
- Page 174 and 175: 168PostersPO-174INDUCTION OF FAS UP
- Page 176 and 177: 170Postersup data were available, m
- Page 178 and 179:
172Posterssamples showing RFC methy
- Page 180 and 181:
174PostersIn the last few years the
- Page 182 and 183:
176PostersPO-187RELAPSED/REFRACTORY
- Page 184 and 185:
178Posters1.The association of prim
- Page 186 and 187:
180Posterswith generalizated lympho
- Page 188 and 189:
182PostersPO-196EPRATUZUMAB/SAPORIN
- Page 190 and 191:
184Postersantioxidant capacity of p
- Page 192 and 193:
186PostersCD16/CD56 + (NK) cells an
- Page 194 and 195:
188Postersby PBSCT, as the general
- Page 196 and 197:
190Postersnode biopsies, three from
- Page 198 and 199:
192PostersPO-212ANALYSIS OF IGV GEN
- Page 200 and 201:
194Postershaematologica vol. 89[sup
- Page 202 and 203:
IIVIII Congress of the Italian Soci
- Page 204 and 205:
IVVIII Congress of the Italian Soci
- Page 206 and 207:
VIVIII Congress of the Italian Soci
- Page 208 and 209:
VIIIVIII Congress of the Italian So
- Page 210 and 211:
XVIII Congress of the Italian Socie